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Condensation 
Sequential enzymatic digest of term human placenta effectively isolates multipotent 
mesenchymal stem cells of maternal origin that remain multipotent in conditions of sub 
confluent expansion.  
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Abstract 
 
OBJECTIVE: This study was undertaken to isolate and characterise multipotent mesenchymal 
stem cells from term human placenta (PD-MSCs).  
STUDY DESIGN: Sequential enzymatic digestion was used to isolate PD-MSCs in which 
trypsin removes the trophoblast layer, followed by collagenase treatment of remaining 
placental tissue. Karyotype, phenotype, growth kinetics, and differentiability of PD-MSCs 
isolates from collagenase digests were analyzed.  
RESULTS: PD-MSC isolation was successful in 14 out of 17 cases. Karyotyping of PD-MSC 
isolates from deliveries with male foetus, revealed that these cells of maternal origin. Flow 
cytometry and immunocytochemistry confirmed the MSC phenotype. Proliferation rates of 
PD-MSCs remained constantly high up to passage 20. These cells could be differentiated 
towards mesodermal lineage in vitro up to passage 20. Non-confluent culture was critical to 
maintain the MSC stemness during long-term culture.  
CONCLUSION: Term placenta constitutes a rich, very reliable source of maternal MSCs that 
remain differentiable even at high passage numbers. 
 
Key words: Human placenta, mesenchymal stem cells, tissue regeneration   
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Introduction 
Mesenchymal stem cells (MSCs) represent an interesting cell type for research and therapy 
because of their ability to differentiate into mesodermal lineage cells such as osteocytes, 
chondrocytes, cardiac muscle, or endothelial cells 1. In addition, they secrete large amounts of 
pro-angiogenic and anti-apoptotic cytokines 2 and possess remarkable immunosuppressive 
properties 3. MSCs have been derived from many different organs and tissues 4 Evidence has 
emerged that also different parts of human placenta, umbilical cord, amniotic membrane, as 
well as umbilical cord blood harbor MSCs. 5-9 These tissues are normally discarded after 
birth, avoiding ethical concerns. 10 Mechanical as well as enzymatic methods for MSC 
isolation from different regions of human placenta of different gestational ages were reported 
(Table 1, see references therein). 5, 11-26 Knowledge about vitality, karyotype, phenotype and 
expandability of such placenta-derived MSC isolates is a prerequisite for therapeutic 
application, however systematic investigations into reliability of this MSC source and 
phenotypic stability have not yet been attempted. Further, former reports on placenta-derived 
MSCs often lack information about the karyotype of the cell isolates. Here we describe 
enzymatic fractionation of term human placenta that allows recovery of multipotent, 
fibroblast-like cells, which we tentatively term as placenta-derived mesenchymal stem cells 
(PD-MSCs) with high fidelity. Unexpectedly, as demonstrated by genotypic analyses of cell 
isolates from male deliveries, the resulting isolates were of maternal, not fetal origin. Our 
systematic characterization of cell isolates from multiple cases showed that these cell isolates 
reproducibly fulfil the general definition of MSCs both by phenotypic and functional criteria. 
27 We demonstrate that maternally-derived PD-MSCs can be greatly expanded, maintain they 
differentiation capacity and stable phenotype up to passage 20.  
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Materials and Methods 
Placenta collection  
The Ethical Committee of the District of Zurich approved the protocol (study Stv22/2006). 
Following written consent, placentas were collected from 17 women donors immediately after 
elective caesarean section in the absence of labor, preterm rupture of membranes, 
chorioamnionitis, or chromosomal abnormalities. Mean maternal age was 32 years (between 
28 and 39 years) and mean gestational age was 38 ±1 weeks. Mean placental weight was 573 
±113 g.  
 
Cell isolation  
Figure 1 depicts the isolation procedure. After removal of decidua and fetal membranes, 
approximately 30g placental tissue was minced and washed three times in physiological 
saline. Blood vessels and clots were removed mechanically. The minced placental tissue was 
subjected to sequential digests with trypsin and collagenase I. First, to remove the 
trophoblastic epithelial cell layer, tissue was incubated in 50mL 0.25% trypsin solution 
containing 80U/mL DNase I (Roche AG, Basel, Switzerland) for 1 h at 37°C. The remaining 
placental fragments were separated in a 250µm metal sieve from the 'trypsin cell suspension'. 
Approximately 15g of placental fragments were subjected to a second digest with collagenase. 
For that, tissue fragments were incubated with 50mL of 12.5U/mL collagenase I (Sigma-
Aldrich AG, Buchs, Switzerland), 80U/mL DNase I for one hour at 37°C. Cell suspensions 
from both trypsin and collagen digests were filtered twice through 100µm cell strainers (BD 
Bioscience, San Jose, CA), then the cells were collected by centrifugation for 5min at 300g. 
The cell pellets were shortly resuspend in hypotonic red blood cell lysis buffer (physiological 
saline with 2mm EDTA, 0.5% BSA, without Ca und Mg, diluted 1:10 with distilled water), 
pelleted again by 5min centrifugation at 300g. Finally, the cells were suspended in 10ml Non 
Hematopoietic Stem Cell Expansion Medium (NH expansion medium; Miltenyi Biotec 
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GmBH, Bergisch-Gladbach, Germany) and plated into a single 75cm2 tissue culture flask 
(TPP AG, Trasadingen, Switzerland) and cultured at 37°C.  
 
Colony assay 
Freshly isolated PD-MSCs, passage 0, were replated at low density, i.e. 50 cells per well of 6-
well plates (TPP), and cultured at 37˚C, 5% CO2 in Non Hematopoietic Stem Cell Expansion 
Medium (NH expansion medium). Outgrowing colonies of spread cells were visualized and 
counted by fluorescence microscopy using rhodamine-labelled phalloidin to stain actin 
cytoskeleton (Invitrogen, Basel, Switzerland), and 4’6-diamidino-2-phenylindole 
dihydrochloride (DAPI; Molecular Probes, Eugene, OR) to stain cell nuclei. Images were 
acquired with a Zeiss Axiovert 200M (Carl Zeiss AG, Feldbach, Switzerland) equipped with a 
digital camera AxioCam MRc, (Carl Zeiss AG, Feldbach, Switzerland).  
 
Growth kinetics 
PD-MSCs of passages 1, 10, and 20 taken from four different cases were plated at 5 x 103 
cells per well in 12 well-plates (TPP) and cultured at 37˚C and 5% CO2 in Non 
Hematopoietic Stem Cell Expansion Medium (NH expansion medium). All experiments were 
performed in triplicate. Cell counts were determined after 24, 48, and 72h culture. For that, 
cells were detached with 0.25% trypsin solution (GIBCO-Invitrogen AG, Basel, Switzerland) 
and counted with a Coulter Z1 cell counter (Instrumenten Gesellschaft AG, Zurich, 
Switzerland). Dead cells were identified by staining with 0.4% trypan blue staining solution 
(Sigma - Aldrich AG).  
 
Antibodies 
Information about primary and secondary antibodies used for flow cytometry and 
immunochemistry is provided in Table 2.  
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Flow cytometry 
Cells were collected by trypsinization. Reaction was performed on live cells, using 105 cells 
per antibody reaction. Cells were incubated for 25min at 4°C. Unstained, non-incubated cells 
serve as controls. Cells were fixed in 4% buffered formalin and analyzed with a flow 
cytometer (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ). A minimum of 104 gated 
events, were acquired for each sample. For staining of the intracellular markers CK-7, α-
SMA, and vWF, cells were fixed in 4% buffered formalin, shortly permeabilized by 10 min 
incubation in 0.9% saponin solution, and then incubated with specific antibodies for 25 min at 
4°C.       
 
Immunocytochemistry 
Briefly, cells on 15 mm glass cover slips (Menzel GmbH + Co KG, Germany) were fixed for 
5 min in 100% acetone, then rehydrated in PBS and blocked with Ultra V Blocking buffer 
(Bio Vision Corporation, England). For staining for intracellular proteins, cells were 
permeabilized with 0.1% Triton X-100 for 3min, then incubated with primary antibodies for 
1h at room temperature. In case of using unconjugated primary antibodies, samples were 
subsequently incubated with secondary polyclonal FITC conjugated goat anti-mouse Ig (BD 
Pharmingen, Switzerland) or FITC-conjugated rabbit anti-rat Ig antibodies (Dako Cytomation, 
Glostrup, Denmark) for 30min at room temperature. All cell samples were additionally 
counterstained with DAPI. Images were taken with a Zeiss Axiovert 200M (Carl Zeiss AG) 
equipped with a digital camera AxioCam MRc, (Carl Zeiss AG) and analysed with AxioVs40 
V 4.5.0.0 imaging software (Carl Zeiss AG). 
 
Cytogenetic analysis 
Chromosome analysis of PD-MSCs cultures, passage 3, from six donors was performed. 
Briefly, metaphase chromosome preparations were performed according to standard 
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procedures at a 400-500 GTG band level. Analysis and identification of the chromosomes was 
performed using a Zeiss Axioplan microscope (Carl Zeiss AG, Feldbach, Switzerland). 
Images were recorded with a Photometrics CCD KAF1400 camera (Photometrics, Tucson, 
AZ) and controlled with smart capture imaging software (Vysis, Inc., Downers Grove, IL). 
 
Fluorescent in situ hybridization analysis for detection of sex determination region 
Fluorescence in situ hybridisation (FISH) studies for detection of sex determination region 
(SRY) were performed using chromosome X (Xp11.1-q11.1, locus DXZ1) and chromosome 
Y (Yp11.1-q11.1, locus DYZ3, alpha satellite) probes Vysis (Abbott Molecular Inc., IL) 
according to the manufacturer’s instructions (Abbot Molecular Inc., Des Planes, IL 60018). 
Analysis of at least 200 metaphases and interphases was performed on PD-MSCs isolated 
from three male deliveries at passage 3 using a Zeiss Axioplan epifluorescence microscope 
(Carl Zeiss AG). Images were recorded by Photometrics CCD KAF1400 camera 
(Photometrics)  and controlled with smart capture imaging software (Vysis, Inc.) 
 
Multipotent differentiation assays 
PD-MSCs, passage 6, from three donors were tested for differentiation towards mesodermal 
lineage in vitro. Differentiation was induced by their culture in commercial differentiation 
media: AdipoDiff, ChondroDiff, and OsteoDiff Induction Media (Miltenyi Biotec GmbH) 
following the manufacturer's protocol. Control cultures were grown in NH expansion medium 
(Miltenyi Biotec GmbH). After differentiation, cells were examined microscopically with a 
Zeiss Axiovert 200M (Carl Zeiss AG). 
 
Adipogenic differentiation 
For adipogenic differentiation, PD-MSCs were cultured at 50 x 103 cells per well of 12 well-
plates in AdipoDiff induction medium (Miltenyi Biotec GmBH) for 3 weeks, with fresh 
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media added every 48h. Oil Red O was utilized to visualize fat droplets. Briefly, cells were 
washed twice with PBS, fixed in pre-cooled methanol for 5 min, rinsed with deionised water, 
and then incubated with 0.5% Oil Red O (Sigma-Aldrich AG) in isopropanol for 20 min at 
room temperature. Finally, stained cells were washed with water and analysed 
microscopically.  
 
 Chondrogenic differentiation 
Chondrogenic differentiation was performed under micromass conditions in ChondroDiff 
induction medium (Miltenyi Biotec GmBH), according to the manufacturer's instructions. 
Briefly, 5 x 106 MSCs were pelleted by 5 min centrifugation at 300g in a cell culture 
centrifuge. The micromass was kept in ChondroDiff medium for 24 days, with fresh media 
added every 48 h. The pellets were fixed in 10% formalin, and then finally embedded in 
paraffin. Staining for proteoglycans was performed on deparaffinised 5 μm sections by 30 
min incubation with 3% Alcian Blue (Sigma-Aldrich AG) in 3% acetic acid, pH 2.5. 
Counterstain was performed with Nuclear Fast Red (DAKO Cytomation). 
 
Osteogenic differentiation 
For osteogenic differentiation, 3 x 104 PD-MSCs were seeded in 12 well plates (TPP) and 
maintained in OsteoDiff induction medium (Miltenyi Biotec GmBH) for 3 weeks, with fresh 
medium added every 48h. After 21 days, cells were fixed in 70% ethanol. Extracellular 
calcium deposition was stained by 45 min incubation with 2% Alizarin Red S (Sigma-Aldrich 
AG) in water. Finally, stained cells were washed with deionised water and analysed 
microscopically. 
 
Angiogenic differentiation 
 9
Angiogenic differentiation was performed as described 28. Briefly, PD-MSCs were seeded at 
the density of 2.5 x 104 cells per well of 12 well plates and cultured for 7 days in Dulbecco's 
Modified Eagle Medium (Invitrogen AG) supplemented with 2% fetal bovine serum 
(Invitrogen AG) and 50 ng/ml vascular endothelial growth factor 121 29. Control cultures 
were performed without VEGF. After 7 days, cells were fixed and stained with mouse anti-
human CD34 antibodies (Miltenyi Biotec GmBH). 
 
Statistical analysis 
Data are shown as mean ± SD. Mann-Whitney (nonparametric) test was performed using 
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA). Data are 
given as mean ± standard deviation. Significance level was set at p< 0.05. 
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Results 
 
Figure 1 depicts the flow chart of the enzyme-mediated fractionation of human term placenta 
for derivation of fibroblast-like cells, which we tentatively term placenta-derived multipotent 
mesenchymal stem cells (PD-MSCs). Selection for MSCs rested on the classic adhesion 
method on tissue culture plastic. The protocol proved successful in 14 out of 17 test cases. 
Cell suspensions produced from by final collagenase I digest of approximately 15 g placental 
tissue fragments typically produced 300-500 colonies of variable sizes that contained 
outgrowing fibroblast-like cells. Typically, approximately 4 to 6 x 104 cells were obtained 
within two weeks after plating. Plating of cell suspensions from the first digest with trypsin 
did not produce any colonies. Outgrowing cells when harvested and replated in high dilution 
rapidly formed secondary colonies from single cells (Figure 2A). PD-MSCs were expandable 
up to passage 20 (as far as we cultured) without change of fibroblast-like morphology (Figure 
2B) or proliferation rate (Figure 2C). Chromosomal analysis of cell isolates from six different 
placental cases (3 of female and 3 of male deliveries) did not show any chromosomal 
abnormalities. Figure 3 gives one example. Karyotypes were normal 46, XX in all test 
samples, including the three PD-MSC isolates obtained from male deliveries (Table 3). FISH 
analysis for the SRY gene confirmed the absence of male cells in our PD-MSC isolates. Thus, 
our procedure isolated only PD-MSCs of maternal origin, which was unexpected. The 
phenotype of the cell isolates, passage 1, was examined by flow cytometry for five cases 
(Figure 4) and further examined by immunocytochemistry with a panel of antibodies against 
30 antigens for a single case (Table 2; Figure 5). Flow cytometry revealed very little scatter in 
the phenotypic marker profile of placenta derived isolates between cases. The expression 
profile conformed to the criteria recently defined for multipotent mesenchymal stem cells. 27 
(Figure 4-5) Cell isolates were uniformly positive for mesenchymal stem cell markers CD44, 
CD73, CD90, CD105, and CD166. Hematopoietic markers CD34, CD45 as well as CD11b, 
CD14, CD19, and CD79alpha were not expressed. Cells stained also negative for macrophage 
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restricted antigen CD163 which marks Hofbauer cells, 30 the cytotrophoblast-specific marker 
cytokeratin 7 31 and syncytiotrophoblast-specific marker placental alkaline phosphatase 
(PLAP). 31 Curiously, the entire cell population was positive for two markers of end-
differentiated cells such as the endothelial protein vWF, and the smooth muscle cell protein α-
smooth muscle actin. PD-MSCs were negative for KDR, cytokeratin 18, CD117 and CD271. 
We found high levels of HLA-ABC but no HLA-DR. Both flow cytometry and 
immunocytochemistry revealed that part of the passage 1 cells expressed the antigen CD133 
which is considered as a marker of non-committed early progenitors of blood cells, 
endothelial cells and other stem cell types. 32,33 Immunocytochemistry did no detect 
expression of human stem cell markers of pluripotency 34 such as the transcription binding 
domains Oct3/4, Stro-1, Tra 1-60, or Tra-1-81. Flow cytometry and immunocytochemistry 
revealed that PD-MSCs were positive for stage-specific embryonic antigen SSeA-3 but 
negative for SSeA-4 (Table 4; Figures 4,5).  
Specific induction of differentiation was investigated with PD-MSCs, passage 6, from three 
cases. This confirmed that the 'mesenchymal stemness profile' by PD-MSCs populations 
indeed associated with the ability to generate different mesodermal lineage cell types upon 
their exposure to soluble factors in vitro. Figure 6 displays representative results of 
adipogenic (A,B) , chondrogenic (C,D) , and osteogenic (E,F) differentiation assays, 
visualizing lipid vacuoles, chondrogenic matrix and calcium deposits, respectively. Moreover, 
culture in presence of the angiogenic growth factor VEGF induced expression of CD34, 
which is marker of hematopoietic as well as endothelial precursors. 35 (Figure 6G,H) The 
latter finding points to a broader mesodermal differentiation capacity of PD-MSCs.  
Sub-confluent culture was found critically important to maintain the 'stemness' phenotype of 
PD-MSCs during expansion. Figure 7 display the results of a side-by-side screen of marker 
profiles of PD-MSCs that were grown in confluent versus sub-confluent culture till passage 
10. The screen was performed with four cases of each condition. The phenotypic profile of 
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PD-MSCs when sub-cultured at 50-70% cell density remained unaffected. In sharp contrast, 
PD-MSCs grown in confluent or near-to confluent culture lost mesenchymal stem cell 
markers almost completely. Expression of CD133 antigen disappeared during culture in both 
conditions.  
PD-MSCs passaged in sub-confluent culture maintained their initial marker profile and their 
ability to differentiate as well. Figures 4B,C depict a direct comparison of the marker profiles 
of passage 1 PD-MSCs versus passage 20 PD-MSCs. Passage 20 PD-MSCs could be induced 
towards chondrogenic and osteogenic lineage in vitro, as demonstrated by staining of 
chondrogenic matrix and calcium deposits, respectively (Figure 8), while adipogenic 
differentiation failed (data not shown).  
 13
Comment 
 
In demonstrating that term human placenta, which is a readily available and ethically 
relatively unproblematic tissue, constitutes a robust source of MSCs, we investigated several 
parameters, namely (1) chromosome number, (2) origin, (3) methods of isolation and (4) 
propagation that are important for their principal utility for cell-based therapy, and could 
influence their proliferative as well as differentiation capacities. Chromosome number was 
found normal in all analyzed PD-MSC isolates (N=6). Looking at maternal or fetal origin, we 
found that PD-MSC isolates obtained with our isolation procedure were always of maternal 
origin, which was contrary to our expectations. This finding corroborates the very recent 
observation by Barlow et al., that cells isolated from placentas of male delivered babies were 
not of fetal origin. In contrast, the study by Fukuchi et al., which is the only investigation, 
reported the detection of fetal origin cells isolated from human term placenta. However, 
looking at the image provided in the same study, a fraction of the isolated cells was of fetal 
origin, while the remaining cells were of maternal origin. The precise placental anatomical 
origin of the maternal cells obtained with our procedure is still unclear. One source could be 
maternal decidua, despite our careful attempts to remove this layer completely before 
digestion of placenta. Placental septa constitute another potential source. One explanation for 
the obvious difficulty to capture fetal mesenchymal stem cells from term human placenta is 
offered by the fact that most of stem cells observed in the first trimester of pregnancy are 
differentiated to cytotrophoblast and endothelium cells in terminal and intermediate villi, 
while the few remaining stem cells were only detectable around the stem villi. 36,37 
Furthermore, the thinning of the stromal layer and decreased cell density towards the end of 
gestation is known as a positive adaptation to ensure the increasing nutritional supply of the 
growing fetus. 38 We think that the most likely origin of the maternal cells obtained in our 
study is decidual tissue that remained on placental septa, which is difficult to remove.  
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Our method of cell isolation by way of sequential digestion of the trophoblast cell layer with 
trypsin and following digestion of remaining placental tissue with collagenase I proved very 
effective for obtaining PD-MSCs. Outgrowth of PD-MSCs from collagenase digests was 
successful in 14 out of 17 test cases, and resulted in populations with remarkably little scatter 
in their MSC profiles between cases. As to propagation, we found out that PD-MSCs must be 
propagated in sub-confluent culture to maintain their MSC profile, because confluent culture 
led to gradual loss of MSC identity. With proper sub-confluent passage, PD-MSCs 
maintained their phenotypic MSC profile up to the highest passage numbers we tested in this 
study, passage 20, as well as their differentiation capacity.  
As detailed in the Results section, cultures of PD-MSCs, after one passage, were constituted 
by a homogenous population of fibroblast-like cells which expressed the typical mesenchymal 
stem cell markers, but showed no contamination with macrophages, hematopoietic cells or 
trophoblast cells (Figure 4A,B). We observed by flow cytometry and immunocytochemistry 
that early passage cultures expressed CD133, a protein of unknown functionality that is 
considered a marker of immature cells. CD133 expression has been found restricted to stem 
cells in normal adult tissue 39, and expressed by non-committed early progenitors of blood 
cells and endothelial cells 32, non-malignant neural progenitors but also as tumor-initiating 
stem cells in brain. 40 Recent studies by Tondreau et al. showed that CD133-positive cell 
fractions of mononuclear cells human peripheral blood and cord blood, which were isolated 
by magnetic sorting with microbeads coated with anti-CD133 antibody, give rise to MSCs. 33 
Magnetic sorting of CD133-positive cells from placental extracts therefore could provide an 
alternative to MSCs selection by adhesion to tissue culture plastic. 
The growth potential of PD-MSC as assessed by their growth kinetics at passages 1, 10, and 
20 was unaffected by subculture. Further, our studies of ‘stemness’ in functional 
differentiation assays showed that PD-MSCs retain their ability to generate chondrocytes and 
osteocytes at passage 20, although adipogenic potential was obviously lost at late passage. 
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Induction with VEGF of endothelial differentiation in early passage PD-MSCs showed that 
the induced cells expressed CD34, a marker for endothelial precursors. We strongly caution 
about an interpretation that PD-MSCs could differentiate into endothelial cells, but rather 
think that this finding could point to a broader plasticity of PD-MSCs.  
In conclusion, we have described a highly reproducible, straightforward methodology that 
leads to isolation of multipotent mesenchymal stem cells of maternal origin from human term 
placenta. Further studies are now indicated to evaluate the properties of such maternally-
derived PD-MSCs regarding their full differentiation capacity in vitro, and ultimately in vivo. 
Aside from evaluating their utility for future cell replacement therapy and tissue engineering, 
we will seek to resolve whether such PD-MSC isolates could become exploited in 
transplantation medicine for an ability to exert immunosuppressive effects 41, and/or to secret 
pro-angiogenic and anti-apoptotic cytokines to aid tissue healing. 2  
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Figure legends 
 
Figure 1. Fractionation scheme for isolation of MSCs from term human placental tissue. The 
procedure till cell plating takes approximately 5 h.  
 
Figure 2. Morphology and growth kinetics of PD-MSCs. (A) Secondary colony formation 
from single cells. Cell shape and organization was analysed by fluorescence microscopy to 
visualize phalloidin-stained F-actin cytoskeleton (red) and DAPI-stained cell nuclei (blue). 
(B) Phase microscopic images of PD-MSCs at indicated passages. (C) Growth kinetics of PD-
MSCs at indicated passages. * indicates significant enhancement (p<0.05) of cell numbers 
between time points. 
 
Figure  3. Representative example of chromosome analysis of PD-MSC cultures at passage 3 
(N=6).  
 
Figure 4. PD-MSC phenotype at passages 1 and 20 as determined by flow cytometry. (A) 
Representative sample of passage 1 PD-MSCs. Green lines denote unstained control cells. (B) 
Screen of PD-MSC isolates, passage 1 (N=5). (C) Screen of PD-MSC isolates, passage 20 
(N=5). 
 
Figure  5. PD-MSC phenotype at passage 6 (N=1) as determined by immunocytochemistry. 
 
Figure 6. Mesodermal lineage differentiation of PD-MSCs in vitro. A representative 
differentiation of PD-MSCs, passage 6 is shown. Cells were kept in induction medium 
(Differentiation) or for control, maintained without induction in standard medium (Control) 
(A,B) Adipogenic differentiation and control as determined by Oil-red-O staining of lipid 
 20
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droplets. (C,D) Chondrogenic differentiation and control as determined by Alcian Blue 
staining of proteoglycans (E,F) Osteogenic differentiation and control as determined by 
Alizarin Red S staining of calcium deposition (G,H) Endothelial differentiation and control as 
determined by CD34 expression in green.  
 
Figure 7. PD-MSC phenotype in sub-confluent versus confluent subculture. (A) 
Representative example of passage 10 PD-MSCs. (B) Screen of PD-MSC isolates, passage 10 
(N=5). Sub-confluent culture was found critically important to maintain MSC marker 
expression.  
 
 
Figure 8. Induced differentiation of PD-MSCs, passage 20. Cells were kept in induction 
medium (Differentiation) or for control, maintained without induction in standard medium 
(Control). (A,B) Chondrogenic differentiation and control as determined by Alcian Blue 
staining of proteoglycans. (C,D) Osteogenic differentiation and control as determined by 
Alizarin Red S staining of calcium deposition. 
 
 
 
 
 
 
 
 
 
 
 











Table 1. Isolation methods for MSCs from human placenta 
 
Stem cell source Gestational age Isolation method Reference 
 
 Whole placental tissue 
 
1st trimester Collagenase + Trypsin 
 
Genbachev et al. 
2005 
 
 Whole placental tissue 1st trimester Trypsin + Collagenase II + Dispase II 
 
Portmann-Lanz et al. 
2006 
 
 
 Whole placental tissue 
 
1st trimester Chorionic villi sampling 
 
Poloni et al. 2008 
 
 Whole placental tissue term Explant culture method 
 
Igura et al. 2004 
Zhang et al. 2006a 
Zhang et al. 2006b 
 
 Central placental lobules term Trypsin Fukuchi et al. 2004 
 Whole placental tissue term Trypsin-EDTA 
 
Yen et al. 2005 
Miao et al. 2006 
Chien et al. 2006 
 
  
 Whole placental tissue 
 
term Collagenase I Barlow et al. 2008 Brooke et al. 2009 
 Whole placental tissue term Collagenase P 
 
Chang et al. 2007 
 
 
Placental tissue without  
stem villi and amniotic 
fetal membranes 
 
term Collagenase + Dispase II Battula et al. 2007 Battula et al. 2008 
 Decidua basalis 2nd trimester 
 
Mechanical mincing 
(no enzymatic digestion) 
 
In‘t Anker et al. 2004
 Decidua parietalis 2nd trimester 
 
Mechanical mincing 
(no enzymatic digestion) 
 
In‘t Anker et al. 2004
 Decidua parietalis term 
 
Collagenase + Hyaluronidase + 
Pronase 
 
Strakova et al. 2008 
 
Table 2. Antibodies used for flow-cytometry and immunocytochemistry 
 
Antigen # Clone Conjugate Host Company 
CD11b ICRF44 PE M BioLegend 
CD14 H5E2 - M BioLegend 
CD19 HIB19 PE M BioLegend 
CD 34 AC136 FITC M Miltenyi Biotec GmbH 
CD 44 G44-26 FITC M BD Pharmingen 
CD 45 5B1. FITC M Miltenyi Biotec GmbH 
CD54 HA58 PE M BD Pharmingen 
CD 73 AD2 PE M BD Pharmingen 
CD79a HM47 PE M BioLegend 
CD 90* 5E10 - M BD Pharmingen 
CD 105* 266 - M BD Pharmingen 
CD 117 YB5.B8 PE M BD Pharmingen 
CD 133/1 AC133 APC M Miltenyi Biotec GmbH 
CD 163 GHI/61 PE M BD Pharmingen 
CD 166 3A6 PE M BD Pharmingen 
CD 271 ME20.4-1H4 PE M Miltenyi Biotec GmbH 
HLA-ABC G46-2.6 FITC M BD Pharmingen 
HLA-DR G46-6 FITC M BD Pharmingen 
Cytokeratin-7 (CK-7) CAM 5.2 FITC M BD Pharmingen 
Cytokeratin-18 (CK-18) CY-90 FITC M SIGMA - ALDRICH AG 
Alpha smooth muscle 
actin (-SMA) 1A4 PE M R&D Systems 
Von Willebrandt factor 
(vWF) 
sheep 
polyclonal FITC S Abcam plc 
KDR / VEGF receptor-2 89106 PE M R&D Systems 
Placental alkaline 
phosphatase (PLAP)* H17E2 - M AbD Serotec 
Hepatocyte specific 
antigen (HSA)* OCH1E5 - M Abcam plc 
SSEA-3** MC-631 - R R&D Systems 
SSEA-4 MC813-70 PE M R&D Systems 
Oct-3/4** 240408 - R R&D Systems 
Vimentin V9 PE M SIGMA - ALDRICH AG 
Nestin* 10C2 - M Abcam plc 
E-Cadherin 36 PE M BD Pharmingen 
Stro-1* STRO-1 - M R&D Systems 
Embryonic stem cell 
marker Tra-1-60* Tra-1-60 - M Abcam plc 
Embryonic stem cell 
marker Tra-1-81* Tra-1-60 - M Abcam plc 
ZO-1 ZO-1-1A12 FITC M Zymed Laboratories 
*  Polyclonal goat anti mouse Ig (BD Pharmingen) 
**  Polyclonal rabbit anti rat Ig (DAKO Cytomation) 
Table 3a. Cytogenetic analysis of PD-MSCs. Data represents karyotyping of passage 3 cell 
isolates obtained from 3 female and 3 male deliveries.  
 
 
 
 
 
Donor 
 
Gender of newborn 
 
 
Normality 
 
Karyotyp 
 
2 
 
 
female 
 
normal 
 
46 XX 
 
4 
 
 
female 
 
normal 
 
46 XX 
 
7 
 
 
female 
 
normal 
 
46 XX 
 
9 
 
 
male 
 
normal 
 
46 XX 
 
11 
 
 
male 
 
normal 
 
46 XX 
 
13 
 
 
male 
 
normal 
 
46 XX 
 
 
 
Table 3b. FISH analysis of PD-MSCs. Data represents sex determining region analysis of 
passage 3 cell isolates obtained from 3 male deliveries 
 
 
 
 
 
Donor 
 
Gender of newborn 
 
 
Normality 
 
Karyotyp 
 
9 
 
 
male 
 
normal 
 
46 XX 
 
11 
 
 
male 
 
normal 
 
46 XX 
 
13 
 
 
male 
 
normal 
 
46 XX 
 
Table 4. Phenotypic analysis of PD-MSCs by flow-cytometry and immunocytochemistry. Data 
represent flow cytometric analysis of passage 1 PD-MSCs and immunocytochemical analysis of 
passage 6 PD-MSCs.  
 
Antigen FACS IC 
   CD11b - n.d. 
   CD14 - n.d. 
   CD19 - n.d. 
  CD34 - - 
  CD44 + + 
  CD45 - - 
  CD54 n.d. 20% 
  CD73 + + 
  CD79a - n.d. 
  CD90 + + 
  CD105 + 30% 
  CD117 - - 
  CD133/1 + 33% 
  CD 163 - n.d. 
  CD166 + + 
  CD271 - - 
  Cytokeratin -7 - - 
  Cytokeratin -18 n.d. 40% 
  KDR - - 
  Placental alkaline phosphatase - - 
  -SMA + + 
  vWF + + 
  Hepatocyte n.d. - 
  HLA-ABC + + 
  HLA-DR - - 
  SSEA-3 + + 
  SSEA-4 - - 
  Oct-3/4 n.d. - 
  Vimentin n.d. + 
  Nestin n.d. 50% 
  E-Cadherin n.d. 40% 
  Stro-1 - - 
  Tra-1-60 n.d. - 
  Tra-1-81  n.d. - 
  ZO-1 n.d. - 
 
